Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting. Pivot, X., Pegram, M. D., Cortes, J., Luftner, D., Rugo, H. S., Lyman, G. H., Curigliano, G., Bondarenko, I., Dvorkin, M., Yoon, Y., Kim, Y., Kim, C. AMER SOC CLINICAL ONCOLOGY. 2020

View details for Web of Science ID 000560368300085